Thymidylate synthase (TS) polymorphism in non-small cell lung cancer (NSCLC) patients

E. Jassem, R. Rosell, M. Taron, R. Dziadziuszko, A. Szymanowska, P. Mendez, E. Martinez, G. Kobierska-Gulida, J. Skokowski, J. Jassem (Gdansk, Poland; Barcelona, Spain)

Source: Annual Congress 2004 - Molecular biology and tumoral markers
Session: Molecular biology and tumoral markers
Session type: Thematic Poster Session
Number: 598
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Jassem, R. Rosell, M. Taron, R. Dziadziuszko, A. Szymanowska, P. Mendez, E. Martinez, G. Kobierska-Gulida, J. Skokowski, J. Jassem (Gdansk, Poland; Barcelona, Spain). Thymidylate synthase (TS) polymorphism in non-small cell lung cancer (NSCLC) patients. Eur Respir J 2004; 24: Suppl. 48, 598

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


Is MIF -173G/C polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010

Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011


Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005

Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010


Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012


Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002

How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015



MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018


Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019

Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020


Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009


Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011


Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004